BCM
PDLI

BlueCrest Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

BlueCrest Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-26,750
Closed -$58K – 710
2019
Q3 		$58K Buy
+26,750
New +$71.5K ﹤0.01% 550
2018
Q4 		– Sell
-191,241
Closed -$503K – 1743
2018
Q3 		$503K Buy
+191,241
New +$469K 0.01% 749
2018
Q2 		– Sell
-30,277
Closed -$89K – 2091
2018
Q1 		$89K Buy
+30,277
New +$82.6K ﹤0.01% 1382
2017
Q4 		– Sell
-25,453
Closed -$86K – 1244
2017
Q3 		$86K Buy
25,453
+14,391
+130% +$40K ﹤0.01% 798
2017
Q2 		$27K Buy
+11,062
New +$25.4K ﹤0.01% 879

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
Engine Capital Management New York $828M AUM 6.49% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return